AMRX's Kashiv deal creates an integrated biosimilars platform, but integration, regulatory execution and product uptake remain key.
Forbes contributors publish independent expert analyses and insights. Joshua Cohen is a Boston-based writer who covers health policy. As of today, July 1st, Cyltezo (adalimumab-adbm) is commercially ...
Panelists discuss how major PBMs' (pharmacy benefit managers) decisions to prefer biosimilars over reference biologics provide valuable insights into successful adoption strategies, specifically ...
Yesafili, an interchangeable biosimilar to Eylea 2 mg, is now commercially available in the United States, according to a ...
Amgen (NASDAQ:AMGN) draws attention as biosimilars and metabolic programs align with a wider turn across the healthcare sector.
Chambers, Ph.D., from Tufts Medical Center, discusses how biosimilars have improved access to biologics, but more work needs to be done for patients to see cost reductions. Biosimilars will continue ...
On July 30, 2026, Meitheal Pharmaceuticals, Inc. (“Meitheal”) announced that the U.S. Food and Drug Administration (“FDA”) has approved ...
Broadly speaking, the Q2 pharma earnings reports paint a picture of an industry willing to continue to spend where they can boost the topline while also reprioritizing efforts that are less profitable ...
Enbrel, a mainstay biologic in the inflammation category, fell 4% overall, with net selling price down 22%. Amgen attributed ...
Establishes an integrated global platform spanning biosimilar R&D, manufacturing and commercialization Adds a major long-term growth pillar ...
WASHINGTON, DC - AUGUST 16, 2022: President Joe Biden (C) signs the Inflation Reduction Act with (L-R) Sen. Joe Manchin (D-WV), Senate Majority Leader Charles Schumer (D-NY), House Majority Whip James ...
Sandoz Group reported higher sales for the second quarter, driven by a strong performance in its biosimilar segment and a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results